NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
MannKind Corporation MNKD
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$349.0M
▲ 22.2% vs FY2024
EPS · FY25
$0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
1.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 349.0M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
USD 0.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin11.1%
Net margin1.7%
Return on assets1.0%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+39.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+51.8%
+39.9%
+73.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.31B
Shares outstanding, FY2025
Change, 5 years+27.1%
Change, 10 years—
The share count grew 27% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 792.2M
total assets, end of FY2025
Total assetsUSD 792.2M
EquityUSD -51.0M
CashUSD 74.9M
Gross debtUSD 354.6M
Net debtUSD 279.8M
Current ratio1.70×
Net debt stands at -548% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.3
0.3
0.2
0.1
0.1
0.1
0.1
0.0
0.0
0.2
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
0.0
0.1
0.0
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
0.1
−0.3
−0.2
−0.2
−0.1
−0.1
−0.2
−0.2
·
·
EBITDA $B
0.0
0.1
0.0
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
0.1
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
·
·
·
Income tax $B
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
·
·
·
·
·
Net income $B
0.0
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
0.1
−0.4
−0.2
−0.2
−0.2
−0.2
−0.2
−0.2
−0.3
−0.3
EPS, diluted $
0.02
0.10
−0.04
−0.34
−0.32
−0.26
−0.27
−0.60
−1.13
1.36
−4.54
−2.57
−0.64
−0.94
−1.32
−1.50
−2.07
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
−1600.0
−134.4
−80.5
Shares out B
0.31
0.30
0.27
0.26
0.25
0.24
0.21
0.19
0.12
0.10
0.09
0.41
0.37
0.29
0.13
0.13
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 46
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed